文献速递姑息放疗与转移瘤放疗物理与技术

骨转移疼痛:SBRT与常规放疗的2期随机对照试验

Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-14

VERTICAL试验在PRESENT队列中随机分配110例疼痛性骨转移患者接受SBRT或常规外照射放疗,主要终点为放疗后3个月疼痛缓解。因干预组选择性脱落,试验检验效能不足。

要点

  • 干预组27%患者拒绝SBRT、16%无法完成SBRT,导致选择性脱落和试验检验效能不足。
  • 两组均未观察到3级或4级毒性。

核心结论

  • 在疼痛性骨转移患者中,SBRT未显著改善放疗后3个月疼痛缓解。
  • 因干预组选择性脱落,试验检验效能不足以检测预设的疼痛缓解差异。

研究设计与样本

  • 单中心2期随机对照试验,嵌套于PRESENT前瞻性队列,纳入因骨转移转诊放疗的患者。
  • 2015年1月29日至2019年3月20日随机分配110例疼痛性骨转移患者至常规外照射放疗或SBRT。
  • 仅干预组获知试验信息并可选择接受或拒绝SBRT;对照组不知情。
  • 主要终点为放疗后3个月疼痛缓解,采用意向治疗和符合方案分析;试验注册号NCT02364115。

主要发现

  • 意向治疗分析纳入常规放疗组44例、SBRT组45例。
  • 干预组12例(27%)拒绝SBRT,7例(16%)无法完成SBRT治疗。

关键数值与推荐

  • SBRT方案:1×18 Gy、3×10 Gy或5×7 Gy。
  • 常规外照射放疗方案:1×8 Gy、5×4 Gy或10×3 Gy。
  • 主要终点为放疗后3个月疼痛缓解;次要终点包括3个月内任意时间疼痛缓解、平均疼痛评分和毒性。

临床怎么用

  • 对于疼痛性骨转移,SBRT与常规外照射放疗在3个月疼痛缓解方面未显示显著差异。
  • 约1/4患者在获知试验后选择常规放疗而非SBRT,约1/5开始SBRT者未能完成治疗,临床决策需考虑患者偏好与治疗完成可行性。

局限性

  • 仅干预组获知试验信息并可拒绝SBRT,导致选择性脱落和试验检验效能不足。
  • 单中心2期试验,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pain response after conventional external beam radiation therapy (cRT) in patients with painful bone metastases is observed in 60% to 70% of patients. The aim of the VERTICAL trial was to investigate whether stereotactic body radiation therapy (SBRT) improves pain response. METHODS AND MATERIALS: This single-center, phase 2, randomized controlled trial was conducted within the PRESENT cohort, which consists of patients referred for radiation therapy of bone metastases to our tertiary center. Cohort participants with painful bone metastases who gave broad informed consent for randomization were randomly assigned to cRT or SBRT. Only patients in the intervention arm received information about the trial and were offered SBRT (1 × 18 Gy, 3 × 10 Gy, or 5 × 7 Gy), which they could accept or refuse. Patients who refused SBRT underwent standard cRT (1 × 8 Gy, 5 × 4 Gy, or 10 × 3 Gy). Patients in the control arm were not informed. Primary endpoint was pain response at 3 months after radiation therapy. Secondary outcomes were pain response at any point within 3 months, mean pain scores, and toxicity. Data were analyzed intention to treat (ITT) and per protocol (PP). This trial was registered with Clinicaltrials.gov, NCT02364115. RESULTS: Between January 29, 2015, and March 20, 2019, 110 patients were randomized. ITT analysis included 44 patients in the cRT arm and 45 patients in the SBRT arm. In the intervention arm, 12 patients (27%) declined SBRT, and 7 patients (16%) were unable to complete the SBRT treatment. In ITT, 14 of 44 patients (32%; 95% confidence interval [CI], 18%-45%) in the control arm and 18 of 45 patients (40%; 95% CI, 26%-54%) in the SBRT arm reported a pain response at 3 months (P = .42). In PP, these proportions were 14 of 44 (32%; 95% CI, 18%-45%) and 12 of 23 patients (46%; 95% CI, 27%-66%), respectively (P = .55). In ITT, a pain response within 3 months was reported by 30 of 44 control patients (82%; 95% CI, 68%-90%) and 38 of 45 patients (84%; 95% CI, 71%-92%) in the SBRT arm (P = .12). In PP, these proportions were 36 of 44 (82%; 95% CI, 68%-90%) and 26 of 27 patients (96%; 95% CI; 81%-100%), respectively (P = .12). No grade 3 or 4 toxicity was observed in either arm. CONCLUSIONS: SBRT did not significantly improve pain response in patients with painful bone metastases. One in 4 patients preferred to undergo cRT over SBRT, and 1 in 5 patients starting SBRT was unable to complete this treatment. Because of this selective dropout, which can be attributed to the character of the intervention, the trial was underpowered to detect the prespecified difference in pain response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pielkenrood BJ, van der Velden JM, van der Linden YM, et al. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort. Int J Radiat Oncol Biol Phys. 2020. PMID: 33333200. doi:10.1016/j.ijrobp.2020.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。